iMeds.se

Medicinsk Oxygen Aga

Information för alternativet: Medicinsk Oxygen Aga 100 % Medicinsk Gas, Komprimerad, visa andra alternativ
Document: Medicinsk Oxygen AGA medicinal gas, compressed ENG SmPC change

SUMMARY OF PRODUCT CHARACTERISTICS


1. NAME OF THE MEDICINAL PRODUCT


Medicinsk Oxygen AGA 100%, Medicinal gas, compressed


2. QUALITATIVE AND QUANTITATIVE COMPOSITION


Oxygen 100% at a pressure of 200 bar (15°C).

Oxygen 100% at a pressure of 153 bar (15°C), 21,3 litre cylinder and bundle 2x21,3 litre


3. PHARMACEUTICAL form


Medicinal gas, compressed

Colourless, odourless and tasteless


4. Clinical particulars


4.1 Therapeutic indications


Oxygen therapy


Hyperbaric oxygen therapy

For treatment of decompression sickness, air/gas emboli from other causes and carbon monoxide poisoning. Treatment of patients who have been exposed to carbon monoxide is especially indicated in pregnant patients or patients who are or have been unconscious, or who have displayed neurological symptoms and/or cardiovascular effects or severe acidosis, irrespective of the measured COHb value.


As adjunct treatment in:

severe osteoradionecrosis, clostridium myonecrosis (gas gangrene).


4.2 Posology and method of administration


Method of administration


Oxygen therapy

Oxygen is administered via the inspiratory air.


Oxygen can also be supplied through a so-called ‘oxygenator’ directly to the blood in cases of, among other things, cardiac surgery with a heart–lung machine, and in other conditions that require extracorporeal circulation.


Oxygen is administered by means of equipment intended for this purpose. With this equipment, the oxygen is supplied to the inspiratory air, and, on expiration, the exhaled gas with any excess of oxygen, passes from the patient and is mixed with the surrounding air (non-rebreathing system). For treatment of cluster headache, oxygen is to be delivered by a facemask, in a non re-breathing system.

For anaesthesia, special equipment is often used in which the exhaled gas recirculates and can, in part, be re-inhaled (circular system with rebreathing).

There are a large number of devices intended for oxygen administration.


Low-flow system:

The simplest system, which mixes oxygen with the inhaled air, e.g. a system in which the oxygen is dosed via a simple rotameter and a nasal catheter or face mask.


High-flow system:

System intended to supply a gas mixture corresponding to the patient’s breath. This system is intended to produce a fixed oxygen concentration that is not affected or diluted by the surrounding air, e.g. Venturimask with a constant oxygen flow in order to give a fixed oxygen concentration in the inhaled air.


Demand valve system

A system designed to deliver 100% oxygen without entrainment of ambient air, intended for short duration of administration when required.


Hyperbaric oxygen therapy:

Hyperbaric oxygen therapy (HBO) is given in specially constructed pressurised chambers intended for hyperbaric oxygen therapy, in which pressures up to the equivalent of 3 atmospheres (atm) can be maintained. HBO can also be given via a very tightly fitting facemask, a hood that fits around the head, or through a tracheal tube.


Posology


Oxygen therapy

The aim of treatment is to ensure, by adjusting the oxygen fraction in the inhaled air (FiO2), that the oxygen partial pressure in arterial blood (PaO2) does not fall below 8.0 kPa (60 mmHg) or that the oxygen saturation of haemoglobin in arterial blood does not fall below 90%.


The dose (FiO2) must be adjusted according to each patient’s individual needs, taking into account the risk of oxygen toxicity. A general recommendation is to use the lowest dose (FiO2) necessary to achieve the desired result of treatment. In cases of pronounced hypoxia, oxygen fractions that can involve a risk of oxygen toxicity may be indicated. (See section 4.9).


The treatment must be continuously evaluated and the effect measured by means of PaO2or arterial oxygen saturation (SpO2).


In short-term treatment with oxygen, the oxygen concentration -the fraction in the inhaled gas mixture (FiO2) (avoid >0.6 = 60% O2in the inhaled gas mixture) - must be kept so that, with or without positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP), an arterial oxygen pressure (PaO2) > 8 kPa can be achieved.


Short-term treatment with oxygen must be monitored/followed with the aid of repeated measurements of arterial oxygen pressure (PaO2) or pulse oximetry, which gives a numerical value for haemoglobin oxygen saturation (SpO2). However, these are only indirect measurements of the oxygen saturation in tissues. The effect of the treatment should also be evaluated clinically.

In the emergency/acute setting the usual dose for adults to treat or prevent acute oxygen deficiency is 3-4 litres per minute when using nasal prongs, or 5-15 litres per minute with a mask.


In long-term treatment, the need for extra oxygen is guided by the result of arterial blood gas measurements. For adjusting oxygen therapy in patients with hypercapnia, blood gases must be monitored in order to avoid a marked increase in arterial carbon dioxide tension.


If the oxygen is mixed with other gases, the concentration of oxygen in the inhaled gas mixture (FiO2) must not be lower than 21% and may be up to 100%.


Administration of pure oxygen (FiO21.0) in the early management of divers exhibiting signs and/or symptoms of diving disease facilitates the diffusion/elimination of nitrogen from the blood and tissues subsequently resulting in reduction of nitrogen bubbles and gas emboli.


In neonates, careful monitoring should be performed during the treatment. The lowest effective concentrations should be sought in order to achieve an adequate oxygenation.


For treatment of cluster headache, oxygen is to be delivered by a facemask, in a non re-breathing system. Oxygen therapy should be instituted early after onset of the attack and should last for about 15 minutes or until the pain has disappeared. Usually a flow of 7 to 10 l/min is sufficient but a flow up to 15 l/min might be necessary to some patients to reach efficacy. Oxygen should be discontinued if no effect occurs after 15 to 20 minutes.


Hyperbaric oxygen therapy

Hyperbaric oxygen therapy (HBO) involves administering 100% oxygen at a pressure exceeding 1.4 times atmospheric pressure at sea level (1 atmosphere = 101.3 kPa = 760 mmHg). For safety reasons the pressure in HBO should not exceed 3 atmospheres. The duration of one treatment session with HBO at a pressure corresponding to 2 to 3 atm is normally between 60 minutes and 4–6 hours, depending on the indication. Treatments may be repeated 2–3 times daily if necessary, depending on the indication and the clinical condition. Repeated treatments are most often necessary for the treatment of soft tissue infections and ischaemic ulcers that do not respond to conventional therapy. HBO must be given by personnel who are competent to do so. Increasing and reducing the pressure must be done slowly in order to avoid the risk of pressure damage (barotrauma).


4.3 Contraindications


There is no absolute contraindication to oxygen therapy.


4.4 Special warnings and precautions for use


High oxygen concentrations should be given for the shortest possible time required to achieve the desired result, and must be monitored with repeated checks of arterial gas pressure (PaO2) or haemoglobin oxygen saturation (SpO2) and the inhaled oxygen concentration (FiO2).


There is evidence in the literature that the risk of oxygen toxicity can be considered negligible if the treatment follows these guidelines:


Neonates are excluded from these guidelines because retrolental fibroplasia occurs with a much lower FiO2. The lowest effective concentrations should be sought in order to achieve an adequate oxygenation appropriate for neonates


Whenever oxygen is used the increased risk for spontaneous ignition should be taken into account. This risk is increased in procedures involving diathermy, defibrillation/ electroconversion therapy.


With high concentrations of oxygen in the inspiratory air/gas, the concentration/pressure of nitrogen is reduced. As a result, the concentration of nitrogen in tissues and lungs (the alveoli) falls. If oxygen is taken up from the alveoli into the blood more rapidly than it is supplied in the inspiratory gas, alveolar collapse can occur (development of atelectasis). The development of atelectatic sections of the lungs leads to a risk of poorer arterial blood oxygen saturation, despite good perfusion, due to lack of gas exchange in the atelectatic sections of the lungs; the ventilation/perfusion ratio worsens, leading to intrapulmonary shunt.


High concentrations of oxygen in vulnerable patients, with reduced sensitivity to the carbon dioxide tension in arterial blood, can cause carbon dioxide retention, which in extreme cases can lead to carbon dioxide narcosis.


In hyperbaric oxygen therapy, the pressure should be increased and reduced slowly in order to avoid the risk of pressure damage (barotrauma).

Hyperbaric oxygen treatment should be used with caution during pregnancy and in females of child bearing potential (see 4.6).


HBO should be used with caution in patients presenting with pneumothorax


4.5 Interaction with other medicinal products and other forms of interaction


The pulmonary toxicity associated with drugs such as bleomycin, amiodarone, furadantin and similar antibiotics, may be exacerbated by inhalation of increased concentration of oxygen


Pregnancy and lactation


Oxygen can be used during pregnancy and lactation.

Hyperbaric oxygen treatment should be used with caution during pregnancy and in females of child bearing potential due to a potential risk of oxidative stress-induced damage in the foetus. In severe carbon monoxide intoxication the benefit vs. risk seems reassuring for the use of hyperbaric oxygen treatment. The use should then be evaluated in each individual patient.


4.7 Effects on ability to drive and use machines


In normal circumstances, medicinal oxygen does not interfere with level of consciousness. Patients who require continuous oxygen support should be evaluated on an individual basis, taking their entire medical situation into account for evaluating if it is recommendable to drive and/or operate complex machinery.


Undesirable effects


Common (>1/100, <1/10):

None


Uncommon (>1/1000, <1/100):

Respiratory, thoracic and mediastinal disorders: Atelectasis, Pleuritis,


Hyperbaric oxygen treatment

Ear and labyrinth disorders: Feeling of pressure in the middle ear, Tympanic membrane rupture


Rare (>1/10,000, <1/1000):

Eye disorders: Retrolental fibroplasia in neonates exposed to high oxygen concentrations.


Very rare (<1/10,000):

Respiratory, thoracic and mediastinal disorders: Respiratory distress syndrome


Hyperbaric oxygen treatment

Central Nervous System: Anxiety, Confusion, Loss of consciousness, Epilepsy unspecified


4.9 Overdose


Overdoses with oxygen do not occur outside treatment in intensive care, and the risks of these are greater with hyperbaric oxygen therapy.


In oxygen intoxication, (symptoms of oxygen toxicity), the oxygen therapy should be reduced or if possible stopped, and symptomatic treatment should be started in order to maintain vital functions (e.g. artificial ventilation/assisted ventilation should be given if the patient shows signs of failing respiration).


5. PHARMACOLOGICAL PROPERTIES


5.1 Pharmacodynamic properties


Pharmaco-therapeutic group :
All other therapeutic products – medical gases, oxygen; ATC code: V03AN01


Oxygen constitutes approx. 21% of air. Oxygen is vital for human life and must be supplied continually to all tissues in order to maintain the cells’ energy production. Oxygen is transported in inhaled air via the airways to the lungs. In the pulmonary alveoli, as a result of the difference in partial pressure, gas exchange takes place from the inhaled air/gas mixture to the capillary blood. The oxygen is transported further in the systemic circulation, for the most part bound to haemoglobin, to capillary beds in the various tissues of the body. The oxygen is transported with the aid of the pressure gradient out to the various cells, its goal being the mitochondria in the individual cells, where it takes part in an enzymatic chain reaction, which creates energy. By increasing the oxygen fraction in the inhaled air/gas mixture, the partial pressure gradient that controls the transport of oxygen to the cells increases.


Administration of pure oxygen (FiO21.0) lowers the nitrogen content in the alveoli thus facilitating the diffusion/elimination of nitrogen from the blood. Reducing the body nitrogen content facilitates the reduction of nitrogen bubbles, gas emboli, such as in subject with signs and/or symptoms of diving disease.


Giving oxygen at a pressure higher than atmospheric pressure (HBO) considerably increases the amount of oxygen that is transported with the blood to the peripheral tissues. Intermittent hyperbaric oxygen therapy causes oxygen transport even within oedematous tissues and tissues with inadequate perfusion, and in this way can maintain cellular energy production and function.

In accordance with Boyle’s law, HBO reduces the volume of gas bubbles in tissues in relation to the pressure with which it is given.


HBO counteracts the growth of anaerobic bacteria.


5.2 Pharmacokinetic properties


Inhaled oxygen is absorbed by a pressure-dependent gas exchange between alveolar gas and the capillary blood that passes the alveoli.


Oxygen is transported by the systemic circulation to all tissues in the body, mainly bound reversibly to haemoglobin. Only a very small proportion is freely dissolved in plasma. On passage through tissue, partial pressure-dependent transport of the oxygen to the individual cells takes place. Oxygen is a vital component in the intermediate metabolism of the cell. It is critical to the cell’s metabolism, among other things, in order to create energy through the aerobic ATP production in the mitochondria.


Oxygen accelerates the release of carbon monoxide that is bound to haemoglobin, myoglobin and other iron-containing proteins, and thus counteracts the negative blocking effects caused by carbon monoxide binding to iron.


Hyperbaric oxygen therapy further accelerates the release of carbon monoxide, compared with 100% oxygen under normal pressure.


Oxygen that is absorbed in the body is eliminated almost completely as carbon dioxide formed in the intermediate metabolism.


5.3 Preclinical safety data


Animal studies have shown that prolonged continous inhalation of pure oxygen may have harmful effects. Tissue injury can be induced in the lung, eye and central nervous system. Marked variability occurs between the time of onset of pathological changes among different species and among animals of the same species.

Hyperbaric oxygen treatment during gestation in mice, rats, hamsters and rabbits led to increased resorptions and foetal abnormalities, and decreased foetal body weights.


6. PHARMACEUTICAL PARTICULARS


6.1 List of excipients


None.


6.2 Incompatibilities


Not relevant.


6.3 Shelf life


3 years for gas cylinders 5 litre.

5 years for gas cylinders 5 litre.


6.4 Special precautions for storage


Storage instructions relating to the medicinal product

This medicinal product does not require any special storage instructions with regard to temperature other than those that apply for gas containers and gas under pressure (see below).

Store gas cylinders in a locked room reserved for medicinal gases (does not apply to a home environment).


Storage instructions relating to gas containers and gases under pressure

Contact with combustible material may cause fire.

Keep away from combustible material.

No smoking.

Risk of explosion in cases of contact with oil and grease.

Must not be exposed to strong heat. If at risk of fire – move to a safe place.

Handle carefully. Ensure that the gas cylinders are not dropped or exposed to knocks.

Keep the cylinder clean and dry. Store in a ventilated place reserved for medicinal gases.

Store and transport with valves closed and, where used, with the protective cap and cover in

place.


Nature and contents of container


The shoulder of the gas cylinder is marked with white paint (oxygen). The body of the gas cylinder is white (medicinal gas). In Finland, the body of the gas cylinder can also be turquoise.

The valves on packages which have integrated pressure regulator and flow selector (Mini-flow, Midi-flow or Maxi-flow) are also called LIV (Linde Integrated Valve).


Container (incl. material) and valves:

Not all pack sizes may be marketed.


1-litre steel cylinder with shut-off valve.

1-litre steel cylinder with shut-off valve with Pin index.

1.1-litre composite cylinder with shut-off valve with integrated manometer/pressure gauge.

1.1-litre composite cylinder with shut-off valve with integrated pressure regulator and flow

selector Mini-flow.

1.2-litre composite cylinder with shut-off valve with integrated manometer/pressure gauge.


2-litre steel cylinder with shut-off valve.

2-litre aluminium cylinder with shut-off valve and integrated pressure regulator.

2-litre composite /alt aluminium cylinder with shut-off valve with integrated pressure regulator.

2-litre composite /alt aluminium cylinder with shut-off valve with integrated pressure regulator and flow selector Mini-flow.

2-litre composite /alt aluminium cylinder with shut-off valve.

2.5 litre steel cylinder with shut-off valve.

2.5 litre steel cylinder with shut-off valve with Pin index.

2.5-litre steel cylinder with shut-off valve with integrated pressure regulator.

3-litre composite cylinder with shut-off valve with integrated pressure regulator and flow selector Maxi-flow.

3-litre composite cylinder, LIV IQ, with shut-off valve, integrated pressure regulator, flow selector Maxi-flow and digital display.


4 litre steel cylinder with shut-off valve.

4 litre steel cylinder with shut-off valve with Pin index.

4,7-litre composite cylinder with shut-off valve


5-litre composite /alt aluminium cylinder with shut-off valve with integrated pressure regulator and flow selector Maxi-flow.

5-litre composite /alt aluminium cylinder, LIV IQ, with shut-off valve, integrated pressure regulator, flow selector Maxi-flow and digital display.

5-litre aluminium cylinder with shut-off valve with integrated pressure regulator and flow selector Midi-flow.

5-litre composite /alt aluminium cylinder with shut-off valve.

5-litre steel cylinder with shut-off valve with integrated pressure regulator.

5-litre steel cylinder with shut-off valve.


6-litre composite cylinder with shut-off valve with integrated manometer/pressure gauge.


10-litre steel cylinder with shut-off valve.

10-litre steel cylinder with shut-off valve with integrated pressure regulator.

10-litre aluminium cylinder with shut-off valve with integrated pressure regulator and flow selector Midi-flow.

10-litre aluminium cylinder with shut-off valve with integrated pressure regulator and flow selector Maxi-flow.


15-litre composite /alt aluminium cylinder with shut-off valve with integrated pressure regulator and flow selector Maxi-flow.

20-litre steel cylinder with shut-off valve.

21,3-litre aluminium cylinder with shut-off valve (153 bar).

50-litre steel cylinder with shut-off valve.

Bundle of 2 x 21,3-litre aluminium cylinders with shut-off valve (153 bar).

Bundle of 10 x 50-litre steel cylinders with shut-off valve.

Bundle of 12 x 50-litre steel cylinders with shut-off valve.


Cylinders/bundles filled to 200 bar, respectively 153 bar*delivers appr X litre gas at atmospheric pressure and 15° C according to the table below:

Cylinder size in litre

1

1.1

1.2

2

2.5

3

4

4,7

5

6

10

15

20

21,3*

50

Litre of gas

210

230

260

430

530

630

850

1000

1060

1260

2120

3180

4200

3450

10 600


Bundle size in litre

2 x 21,3*

10x50

12x50

Litre of gas

6900

106 000

128 000


Special precautions for disposal and other handling


Instructions for use and handling


General

Medicinal gases must only be used for medicinal purposes.

Different gas types and gas qualities must be separated from each other. Full and empty containers must be stored separately.

Never use oil or grease, even if the cylinder valve is stiff or if the regulator is difficult to connect. Handle valves and devices to match with clean and grease-free (hand cream, etc.) hands.

Use only standard equipment that is intended for medicinal oxygen.

Check that the cylinders are sealed before they are taken into use.

Prior to any use, ensure the sufficient quantity of product remains to allow completion of the planned administration.

Cylinders equipped with the so called LIV valve have the pressure regulator incoporated in the valve. A separate pressure regulator is therefore not needed. The LIV valve has a standard quick connector to be used with specific devices. There is also a separate outlet for continuous flow which may be adjusted to required administration flow.


Preparation for use

Remove the seal from the valve before use.

Use only regulators intended for medicinal oxygen. Check that the automatic coupling or regulator is clean and that the gaskets are in good condition.

Never use a tool on a stuck pressure/flow regulator intended to be connected manually, as this can damage the coupling.

Open the cylinder valve slowly – at least half a turn.

Check for leakage in accordance with the instruction that accompanies the regulator. Do not try to deal with leakage from the valve or device yourself other than by changing the gasket or O-ring.

In the event of leakage, close the valve and uncouple the regulator. Label defective cylinders, put them aside and return them to the supplier.


Using the gas cylinder

Smoking and open flames are absolutely forbidden in rooms where oxygen therapy is being carried out.

Close down the equipment in the event of fire or if it is not being used.

Carry to safety in the event of fire.

Larger gas cylinders must be transported by means of a suitable type of cylinder trolley. Take special care that connected devices are not inadvertently loosened.

When the cylinder is in use it must be fixed in a suitable support.

For cylinders equipped with integrated valves, the user should be prepared to change the cylinder when the pressure gauge is in the yellow zone and change it when it enters the red zone.

When a small amount of gas is left in the gas cylinder (approx. 2 bar), the cylinder valve must be closed. It is important to leave a little pressure in the cylinder to protect it from contamination.

After use, the cylinder valve must be closed hand-tight. Depressurise the regulator or

connection.


7. MARKETING AUTHORISATION HOLDER


AGA AB

SE-181 81 Lidingö, Sweden


8. MARKETING AUTHORISATION NUMBER(S)


18687


9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION


2005-08-04 / 2010-08-04



10. DATE OF REVISION OF THE TEXT


2015-08-20

10(10)